氟，羟乙磷酸钠和1，25双羟维生素D_3干预对去卵巢大鼠骨的骨计量学和生物力学性质的影响
|
摘要
氟主要通过刺激成骨前体细胞的增殖达到刺激骨形成，增加骨量的效应。活性维生素D_3是一种分化诱导因子，能诱导成骨前体细胞分化成熟。骨计骨学研究表明：氟治疗骨质疏松常伴有矿化缺陷和继发性甲状旁腺功能亢进(甲旁亢)的表现，提示在氟的强烈的刺激成骨作用下，有钙缺乏状态存在。因此，联合应用氟和活性维生素D_3，不仅有可能通过刺激成骨前体细胞的增殖和分化成熟两个环节，产生更大的成骨效应，还能促进肠钙的吸收，纠正氟治疗引起的钙缺乏状态，消除矿化缺陷和继发性甲旁亢，达到增加骨的力学性质和抗骨折能力的目的。
双磷酸盐是无机焦磷酸盐的类似物，它主要通过抑制破骨细胞的募集和破骨前体细胞的分化成熟，从而抑制骨吸收，降低骨转换，在骨计量学上表现为降低小梁骨的“吸收深度”和“刺激频率”，因而能减少“穿孔”吸收的发生，保护骨的的显微结构。氟虽能刺激骨的形成，但并不影响骨的转换，在高的骨转换状态下，氟治疗有可能加重骨的矿化异常，导致骨力学稳定性的破坏，因此，联合应用刺激骨形成的氟和抑制骨吸收的双磷酸盐，可能达到增加骨量，减少“穿孔”吸收，抑制骨转换，改善骨的力学性质，增加抗骨折效应的目的。
本研究，选用4 1／2月龄的健康雌性Wistar大鼠48只，随机分为六组：假手术组(Sham)，去卵巢不处理组(OVX)，去卵巢单用氟钙制剂处理组(0.45mgF~-+13.56mg ca~(++)／kg／d)(O+F)，和氟钙制剂与1、25(OH)_2D_3联合处理组(0.45mgF~-+13.56mg ca~(++)／kg／d+135pmol 1，25(OH)_2D_3／d)(O+F+D)，去卵巢单用羟乙磷酸钠处理组(1mg／kg／d)(O+EP)和氟钙制剂与羟乙磷酸钠联合用药组(0.45mgF~-+13.56mg ca~(++)+1mg EHDP／kg／d)。采用预防性给药方式，共给药7周。我们研究了这四种不同干预措施对胫骨干骺端次级小梁骨的骨计量学指标和股骨中段生物力学性质影响，结果发现：
①去卵巢组与假手术组比较，去卵巢组大鼠的刺激频率增加74％(P＜0.001)，破骨细胞侵蚀表面增加100％(P＜0.05)。小梁骨数量减少49％(P＜0.05)，小梁骨分离度增加80％(P＜0.001)，而小梁骨面积减少39.4％(P＜0.05)，表明去卵巢早期(7周)，破骨细胞活性增加，骨转换加速，小梁骨骨量的丢失主要是由于“穿孔”吸收导致显微结构的破坏所致。
②与OVX组比较O+F组，O+F+D组，O+EP组和O+EP+F组小
Fluoride stimulates the bone formation and increases bone mass by means of stimulating mainly proliferation of osteoblast precursors. 1,25-dihydroxyvitamin D., a differentiation agent, can induces differentiation of osteoblast. A recent histomorphometric study demonstrated that fluoride treatment of osteoporosis may result in defect of mineralization and secondary hyperparathyroidism. These findings suggested that the strong stimulus for bone formation brought about by fluoride therapy led to relative calcium deficiency. Thus, use of a combination of fluoride and 1,25-dihydroxyvitamin D_3 can produced greater effect on bone formation by ttimulating both the differentiation and proliferation of osteoblast precursors. 1,25-dihydroxyvitamin D_3can promote intestinal absorption of calcium, correct calcium deficiency, eliminate the defects of mineralization and secondary hyperparathyroidism resulted from fluoride therapy. We supposed a combination of fluoride and 1,25(OH)_2D_3 treatment may increase bone mechanical strength, then enhance antifracture efficacy.
Bisphosphonates are analogues of pyrophosphate. They can inhibit osteoclast-mediated resorption of bone, decrease bone turnover by inhibiting the recruitment of osteoclast and differentiation of osteoclast precursors. These effects manifest as decrease of resorption depth and activation frequency in histomorphometric analysis. By which bisphosphonate can decrease "perforation" resorption of trabeculae to protect bone microarchitecture. Althought fluoride can stimulate bone formation, but no effect on bone turnover. In high bone turnover, fluoride may aggravate defect of mineralization, lead to a destroy in mechanical stability of the skeleton,therefore, use of fluoride stimulating bone formation and bisphosphonates inhibiting bone resorption at the same time may augment bone mass, decrease "perforation" resorption, inhibit bone turnover, improve mechanical properties of bone, enhance antifracture efficacy. At present study, 48 four and a half month old virgin female Wistar rats were randomly divided into six groups: ovariectomized group (OVX), sham-operated group, OVX treated with fluoride-Ca (0. 45ngF~ + 13. 56mg Ca~(++)/kg/d) (O+F), OVX treated with combination of fluoride-Ca and 1, 25-dihydroxyvitamin D_3 (0. 45mgF~- + 13.56mg Ca~(++)/kg/d + 135pmol 1, 25(OH)_2D_3,/d), (O+F + D), OVX treated with disodium ethane-l-hydroxy-l,1-bisphosphonate (EHDP 1mg/kg/d) (O + EP), OVX treated with combination of EHDP and fluoride-Ca (O+EP+F). Administration in a preventive mode lasted for seven weaks after OVX. We observed the
双磷酸盐是无机焦磷酸盐的类似物，它主要通过抑制破骨细胞的募集和破骨前体细胞的分化成熟，从而抑制骨吸收，降低骨转换，在骨计量学上表现为降低小梁骨的“吸收深度”和“刺激频率”，因而能减少“穿孔”吸收的发生，保护骨的的显微结构。氟虽能刺激骨的形成，但并不影响骨的转换，在高的骨转换状态下，氟治疗有可能加重骨的矿化异常，导致骨力学稳定性的破坏，因此，联合应用刺激骨形成的氟和抑制骨吸收的双磷酸盐，可能达到增加骨量，减少“穿孔”吸收，抑制骨转换，改善骨的力学性质，增加抗骨折效应的目的。
本研究，选用4 1／2月龄的健康雌性Wistar大鼠48只，随机分为六组：假手术组(Sham)，去卵巢不处理组(OVX)，去卵巢单用氟钙制剂处理组(0.45mgF~-+13.56mg ca~(++)／kg／d)(O+F)，和氟钙制剂与1、25(OH)_2D_3联合处理组(0.45mgF~-+13.56mg ca~(++)／kg／d+135pmol 1，25(OH)_2D_3／d)(O+F+D)，去卵巢单用羟乙磷酸钠处理组(1mg／kg／d)(O+EP)和氟钙制剂与羟乙磷酸钠联合用药组(0.45mgF~-+13.56mg ca~(++)+1mg EHDP／kg／d)。采用预防性给药方式，共给药7周。我们研究了这四种不同干预措施对胫骨干骺端次级小梁骨的骨计量学指标和股骨中段生物力学性质影响，结果发现：
①去卵巢组与假手术组比较，去卵巢组大鼠的刺激频率增加74％(P＜0.001)，破骨细胞侵蚀表面增加100％(P＜0.05)。小梁骨数量减少49％(P＜0.05)，小梁骨分离度增加80％(P＜0.001)，而小梁骨面积减少39.4％(P＜0.05)，表明去卵巢早期(7周)，破骨细胞活性增加，骨转换加速，小梁骨骨量的丢失主要是由于“穿孔”吸收导致显微结构的破坏所致。
②与OVX组比较O+F组，O+F+D组，O+EP组和O+EP+F组小
Fluoride stimulates the bone formation and increases bone mass by means of stimulating mainly proliferation of osteoblast precursors. 1,25-dihydroxyvitamin D., a differentiation agent, can induces differentiation of osteoblast. A recent histomorphometric study demonstrated that fluoride treatment of osteoporosis may result in defect of mineralization and secondary hyperparathyroidism. These findings suggested that the strong stimulus for bone formation brought about by fluoride therapy led to relative calcium deficiency. Thus, use of a combination of fluoride and 1,25-dihydroxyvitamin D_3 can produced greater effect on bone formation by ttimulating both the differentiation and proliferation of osteoblast precursors. 1,25-dihydroxyvitamin D_3can promote intestinal absorption of calcium, correct calcium deficiency, eliminate the defects of mineralization and secondary hyperparathyroidism resulted from fluoride therapy. We supposed a combination of fluoride and 1,25(OH)_2D_3 treatment may increase bone mechanical strength, then enhance antifracture efficacy.
Bisphosphonates are analogues of pyrophosphate. They can inhibit osteoclast-mediated resorption of bone, decrease bone turnover by inhibiting the recruitment of osteoclast and differentiation of osteoclast precursors. These effects manifest as decrease of resorption depth and activation frequency in histomorphometric analysis. By which bisphosphonate can decrease "perforation" resorption of trabeculae to protect bone microarchitecture. Althought fluoride can stimulate bone formation, but no effect on bone turnover. In high bone turnover, fluoride may aggravate defect of mineralization, lead to a destroy in mechanical stability of the skeleton,therefore, use of fluoride stimulating bone formation and bisphosphonates inhibiting bone resorption at the same time may augment bone mass, decrease "perforation" resorption, inhibit bone turnover, improve mechanical properties of bone, enhance antifracture efficacy. At present study, 48 four and a half month old virgin female Wistar rats were randomly divided into six groups: ovariectomized group (OVX), sham-operated group, OVX treated with fluoride-Ca (0. 45ngF~ + 13. 56mg Ca~(++)/kg/d) (O+F), OVX treated with combination of fluoride-Ca and 1, 25-dihydroxyvitamin D_3 (0. 45mgF~- + 13.56mg Ca~(++)/kg/d + 135pmol 1, 25(OH)_2D_3,/d), (O+F + D), OVX treated with disodium ethane-l-hydroxy-l,1-bisphosphonate (EHDP 1mg/kg/d) (O + EP), OVX treated with combination of EHDP and fluoride-Ca (O+EP+F). Administration in a preventive mode lasted for seven weaks after OVX. We observed the
引文
1. Consensus development conference Prophylaxis and treatment of osteoporosis. Am J Med 90:107-110, 1991.
2. Robert Lindsay: Fluoride and bone-quantity versus quality. N Engl J Med 322 (12):845-846, 1990.
3. Melton LJ, Kan SH, Frye MA, etal: Epidemiology of vertebral fractures in women. American Joumal of Epidemiology. 129:1000-1011, 1989.
4. Cummings SR , Kelsey JL, Nevitt MC, etal: Epidemiology of osteoporosis and os- teoporotic fractures. Epidemiological Reviews 7:178-208, 1985.
5. L Joseph Melton III : How much women have osteoporosis now? J Bone Miner Res 10(2),175-177, 1995.
6.TJ Martin, Kong Wah Ng, Tatsuo Suda: Bone cell physiology. Endocrinology and Metabolism Clinics of North America 18(4): 833-857, 1989.
7.M Arlot, C Edouard, PJ Meunier etal: Impaired osteoblast function in osteoporosis : comparison between calcium balance and dynamic histomorphometry. British Medical Journal 289:517-520, 1984.
8. Lundy M W, Wergedal JE, Teubner E, etal : The effect of prolonged fluoride therapy for osteoporosis bone composition and histology. Bone 10.321-327, 1989.
9. Kleerekoper M, Peterson EL, Nelson DA etal: A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1:155-161, 1991.
10. Farley JR, Wergedal JE, Baylink DJ: Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone forming cells. Science 222:330-332, 1983.
11. Moustapha kassem, Leif Mosekilde, and Erik Fink Eriksen: 1,25-Dihydroxyvi-tamin D_3 potentiation fluoride stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cells. J Bone Miner Res 8(12) : 1453-1458, 1993.
12. Riggs BL , Hodgson SF, O' Falion WM , etal: Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809, 1990.
13. MW Lundy, M Stauffer, JE Wergedal etal: Histomorphometric analysis of iliac crest bone biopsies in placebo-treated versus fluoride-treated subjects. Osteoporosis Int 5:115-129, 1995.
14. N Mamelle, PJ Meunier R Dusan etal: Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 2:361-365, 1988
15. BL Riggs, WM O' Fallon, A Lane etal: Clinical trial of fluoride therapy in post-??menopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 9(2):265-275, 1994.
16. Helmut Reichel, H Phillip Koeffler, and Anthony W Norman: The role of the vitamin D endocrine system in health and disease. N Engl J Med 320(15):980-991, 1989.
17. Marie-claude Faugere, Sumiaki Okamoto, Hector F Deluca: Calcitroil corrects bone loss induced by oophorectomy in rats. Am J physiol 250:E35-E38, 1986.
18. Kleerekoper M , Balena R: Fluoride and ostooporosis Annu Rev Nutr 11:309-324, 1991.
19.Fleish H: Bisphosphonates. Drugs 42:919-44, 1991.
20. Kanis JA: Pathophysiology and treatment of Paget's disease of bone London: Martin Dunitz 1991.
21. Russell RGG, Kanis JA: Tumor-induced hypercalccmia and its management. Royal Society of Medicine International Congress and Symposium Series 176 London: RSM 1991.
22. Tommy Sterm, Torben Steiniche, Gorm Thamsborg etal: Changes in bone histo-mophometry after Long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8(2):199-208, 1993.
23. Erik Fink Eriksen, Torben Steiniche, Leif Mosekilde etal: Histomorphometric analysis of bone in metabolic bone disease. Endocrinology and Metabslism Clinics of North American 18(4):919-954, 1989.
24. P Fratzl, P Roschger, J Eschberger etal: Abnormal bone mineralization after fluoride treatment in osteoporosis: A small angle X-ray-scattering study J Bone Miner Res 9(10):1541-1549, 1994.
25. Etsuji Shiota: Effects of diphosphonate on osteoporosis induced in rats, roen-togenological, histological and biomechanical studies. Fukuoka Acta Med 76(6): 317-342, 1985.
26. Roland Baron, Agnes Vignery, Lynn Neff etal: Processing of undecalcified bone specimens for bone histomophometry. In Recker RR (ed): Bone histomor-phometry techniques and interpretation. Boca Raton Florida CRC Press Inc 1983 pl4-30
27.XJ Li, WSS Jee, HZ ke, etal: Age-related changes of cancellous and cortical bone histomorphometry in female Sprague-Dawley rats. Cell and Material (Suppl) l: 25, 1991.
28. Takashi Katsumata, Toshitaka Nakamura, Hideo Ohnishi etal: Intermittent Cyclical etidronate treatment maintain the mass, structure and mechanical property of bone in ovariectomized rats. J Bone Miner Res 10(6) : 921-931, 1995.29．王以进，王介麟编著 骨科生物力学。北京：人民军医出版社1989
30．孟迅吾，刑小平，陈莉等：血清抗酒石酸酸性磷酸酶浓度测定的初步临床应用．中华内分泌代谢杂志11(1)：9-11，1995
31. GR Mundy: Visions for the future in osteoporosis research. Osteoporosis Int (Suppl) 2: s29-34, 1993
32. TJ Wronski and CF Yen: The ovariectomized rat as an animal model for postmenopausal bone loss. Cell and Material (suppl) 1: 69-74, 1991.
33. Frost HM and WSS Jee: On the rat model of human osteopenias and osteoporosis Bone Miner 18: 227-236, 1992.
34. Mosekilde Li and Sgaard CH: Assessing bone quality. The International Conference on Animal Models in the Prevention and Treatment of Osteopenia (Abstract) 1995, p1
35. DD Thompson: Animal models and the FDA guidelines for osteoporosis. The International Conference on Animal Models in the Prevention and Treatment of Osteopenia (Abstract) 1995, p1
36. Kalu DN: The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15: 175-192, 1991.
37. TJ Wronski, PLLowry, CC Walsh et al: Skeletal alteration in ovariectomized rats. Calcif Tissue Int. 37: 324-328, 1985.
38. JD Ringe and PJ Meunier: What is the future for fluoride in the treatment of osteoporosis? Osteoporosis Int 5: 71-74, 1995.
39. Pascale Chavassieux, Chantal Chenu, Alexandre Valentin-Opran et al: In vitro exposure to sodium fluoride does not modify activity or proliferation of human osteoblastic cells in primary cultures. J Bone Miner Res 8(1): 37-45, 1993.
40. Robert P, Heaney David J Baylink, C Conrad Johnston, Jr et al: Fluoride therapy for the vertebral crush fracture syndrome. A status report. Annals of Internal Medicine 111(8): 678-680, 1989.
41. R Hall, G Embery, R Waddington et al: The influence of fluoride on the adsorption of proteoglycans and glycosaminoglycans to hydroxyapatite. Caleif Tissue Int. 56: 236-239, 1995.
42. Beresford JN, Gallagher JA, Poser JW, et al: Production of osteocalcin by human bone cells in vitro effects of 1α25 (OH)_2D_3 parathyroid hormone and glueocorticoids. Metab Bone Dis 5: 229-235, 1984
43. Price PA, Baukol SA: 1,25-Dihydroxyvitamin D_3 increases synthesis of the vitamin k-dependent bone protein by osteosarcoma cells J Biol chem 255: 11660-11663, 1980.
44. Chenu C, Valentin-Operan A, Chavassieux P, et al: Insulin-like growth factor I??(IGF-I) hormonal regulation by growth hormoneand 1,25(OH)_2D_3, and activity on human osteoblast-like cells in short-term cultures. Bone 11:81-86, 1990.
45. Petkovich PM, Wrana JL, Grigoriadis AE etal: 1, 25-dihydroxyvitamin D_(?) increases epidermal growth factor receptors and transforming growth factor β-like activity in a bone-derived cell line J Biol Chem 262:13424-8, 1987.
46. Berenice Y Reed, Joseph E Zerwekh, Peter P Antich etal: Fluoride-stimulated [~3H] thymidine uptake in a human osteoblastic osteosarcoma cell line is dependent on transforming growth factor β. J Bone Miner Res 8(1): 19-25, 1993.
47. Dempster DW, Li X-F, Birchmaan RV, Shen R etal: On the mechanism of can-cellous bone loss in the ovariectomized rat. Bone Miner 17:s29, 1992.
48. DB Lauritzen, R Balzna, M Shea etal: Effect of combinated prostaglandin and Al-endronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats. J Bone Miner Res 8(7):871-879, 1993
49. Pierre J Marie and Monique Hott: Short-term effects of fluoride and strontium on bone formation and resorption in the mouse. Metabolism 35(6) :547-551, 1986.
50. Briancon D, Meunier PJ: Treatment of osteoporosis with fluoride, calcium and vitamin D. Orthop Clin North AM 12:629-648, 1981.
51. Sahni M , Guenther HL, Fleisch H, etal: Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004-11, 1993.
52. Stronski SA, L Bettschen-Camin, A Wetterwald etal: Bisphosphonates inhibit 1, 25-dihydroxyvitamin D_3-induced increase of osteocalcin in plasma of rats in vivo and in culture medium. Calcif Tissue Int 42:248-254, 1988.
53. Ohya K , S Yamada, R Felix etal: Effect of bisphosphonates on prostaglandin synthesis by rat bone cells and mouse calvaria in culture. Clin Sci (Lond) 69:403-411, 1985.
54. Lenehan TM, Balligand M, Nunamaker DM, etal: Effects of EHDP on fracture healing in dogs. J Orthop Res 3:499-507, 1985
55. Flora L, Hassing GS, Parfitt AM etal: Comparative skeletal effects of two diphosphonates in dogs. Metab Bone Dis Rel Res 2:389-407, 1980.
56. Dominique Modrowski, Livia Miravet, Michel Feuga etal: Effect of fluoride on bone and bone cells in ovariectomized rats. J Bone Miner Res 7(8): 961-969, 1992.1. Consensus development conference Prophylaxis and treatment of osteoporosis. Am L Med 90: 107-110, 1991
2. Robert Lindsay: Fluoride and bone-quantity versus quality. N Eng1 J Med 322(12):845-846, 1991
3. Melton LJ, Kan SH, Frye MA, etal: Epidemiology of vertebral fractures in women. American Journal of Epidemiology 129:1000-1011, 1989.
4. Cummings SR, kelsey JL , Nevitt MC, etal: Epidemiology of osteoporosis and osteoporotic fractures. Epidemiological Reviews 7: 178-208, 1985.
5. L. Joseph Melton III : How much women have osteoporosis now? J Bone Miner Res 10(2) : 175-177, 1995.
6. Riggs BL, Hodgson SF, O' Fallon WM etal: Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809, 1990.
7. Kleerekoper M, Peterson EL, Nelson DA etal: A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int. 1:155-161, 1991.
8. Pierre J. Marie and Monique Hott: Short-term effects of fluoride and strontium on bone formation and resorption in the mouse. Metabolism. 35(6).547-551, 1986.
9. Gillian R Show and C Anderson: Short-term chronic fluoride administration and trabecular bone remodeling in beagles: A polit study. Calcif Tissue Int 38:217-221, 1986.
10. Dominique Modrowski, Livia Miravet etal: Effect of fluoride on bone and bone cell in ovariectomized rat. J Bone Miner Res 7(8): 961-969, 1992.
11. J Kragstrag , Richards A , Fejerskov etal: Experimental osteo-fluorosis in the domestic pig A histomorphometric study of vertebral trabecular bone. J Dent Res 63(6):885-889 June. 1984.
12. Aaron JE, De vernejoul MC, Kanis JA: The effect of sodium fluoride on trabecular architecture. Bone. 12:307-310,1991.
13. Lafage MH ,Balena R, etal: Comparison of alendronate and sodium flu-oride effects in minipigs : one year study. Calcif Tissue Int. 52 (Suppl 1):s96,1993.
14. Thomas A Einhorn, GK Wakey, etal: Incorporation of sodium fluoride into cortical bone does not impair the mechanical properties of the ap- pendicular skeleton in rat. Calcif Tissue Int. 51:127-131,1992.
15. MW Lundy, M Stauffer etal: Histomorpometric analysis of iliac crest bone biopsies in placebo-treated versus fluoride-treated subjects. Osteoporosis Int 5:115-129,1995.
16. Hall BK : Sodium fluoride as an initiator of osteogenesis from embryonic mesenchyme in vitro. Bone 8:111-116, 1987.
17. Farley JR, Wergedal JE , Baylink DJ: Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone forming cells. Science 223:330-332, 1983.
18. Farley JR, Nanine Tarbaux, Susan Hall etal: Evidence that fluoride-stimulated ~3[H]-thymidine incorporation in embryonic chick calvarial cultures is dependent on the presence of a bone cell mitogen sensitive to changes in the phosphate concentration and modulated by systemic skeletal effectors. Metabolism 37:988-995, 1988.
19.BY Reed, Joseph E Zerwekh, Peter D Autich etal: Fluoride-stimulated ~3[h] thymidine uptake in a human osteoblastic osteosarcoma cell line is dependent on transforming growth factor β. J Bone Miner Res 8(1) : 19-25, 1993
20. M Kassem , Leif Mosekilde and Erik Fink Eriksen: 1,25-dihydroxyvi- tamin D_3 potentiates fluoride-stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cells. J Bone Miner Res 8(12) : 1453-1458,1993.
21. Pascale chavassieux, Chantal Chenu, Alexandre Valentin-Opran etal: In vitro exposure to sodium fluoride does not modify activity or proliferation of human osteoblastic cells in primary cultures. J Bone Miner Res. 8(1),37-44,1993.
22. Marie PJ, De. Vernejoul MC, Lomri A : Stimulation of bone formation in osteoporosis patients treated with fluoride associated with increased DNA synthesis by osteoblastic cells in vitro J Bone Miner Res. 7:103- 113, 1992.
23. Farley JR, Tarbaux N , Hell S,etal: Mitogenic action (s) of fluoride on osteoblast-like cells:Determinants of the response in vitro J Bone Miner Res. 5:s107-s113, 1990.
24. Gruber HE, Baylink DJ: The effects of fluoride on bone. Clin Orthop Rel Res 267: 264-277, 1991.
25. Lau KHW, Farley JR, Freeman TK, etal: A proposed mechanism of the mitogenic action of fluoride on bone cells :inhibition of activity of an osteoblastic acid phosphatase. Metabolism 38:858-868,1989.
26. D Burgener, J-P Bonjour and J Caverzasio: Fluoride increase tyrosine kinase activity in osteoblast-like cell :regulatory role for the stimulation of cell proliferation and Pi transport across the plasma membrane. J Bone Miner Res. 10(1) : 164-171,1995.
27. Kato I Yoneda T, etal:Osteoclasts deficiency in c-src tyrosine kinase fail to resorb bone in vitro and in vivo. J Bone Miner Res 6:[Suppl]:ab- str 452,1991.
28. Dziewiatowski DD: Binding of calcium by proteoglycans in vitro. Calcif Tissue Int. 40:265-269,1987.
29. Templeton DM : Metal binding properties of the isolated glomerular basement membrane. Biochim Biophys Acta 926:94-105,1987.
30. Fujisawa R, Kuboki Y: Preferential adsorption of dentine and bone acidic proteins on the (100) face of hydroxyapatite crystals. Biochim Biophys Acta. 1075:56-60, 1991.
31. Smalley JW, Embery G: The influence of fluoride administration on the structure of proteoglycans in the developing rat incisor. Biochem J. 190:263-272,1980.
32. Waddington RJ, Embery G etal: The influence of fluoride on proteo- glycan structure using a rat odontoblast in vitro system. Calcif Tissue Int. 52:392-398, 1993.
33. Susheela AK , Sharma K,etal: The status of sulfated isomers of gly- cosaminoglycans in fluorosed human teeth. Archs Oral Biol 33:765-767, 1988.
34. Susheela AK , Mukergee D: Fluoride poisoning and the effect on collagen biosynthesis of osseous and non osseous tissue of rabbit. Toxicol Eur Res. 2:99-104, 1981.
35. Sharma. YD: Effect of sodium fluoride on collagen cross-link precursors. Toxicol Lett 10:97-100,1982.
36. Sharma YD: Variations in the metabolism and maturation of collagen after fluoride ingestion. Biochim Biophys Acta 715:137-141,1982.
37. Embery G, Rolla G, etal: Interaction of acidic glycosaminoglycans (mucopolysaccharides) with hydroxyapatite. Scand J Dent Res 23-13- 17,1979.
38. R Hall, G Embery etal : The influence of fluoride on the adsorption of proteoglycans and glycosaminoglycans to hydroxyapatite. Calcif Tissue Int. 56.236-239,1995.
39. P Fratzl, P Roschger etal: Abnormal bone mineralization after fluoride treatment in osteoporosis:A small-angle x-ray-scattering study. J Bone and Miner Res. 9(10) : 1541-1549,1994.
40. Mark W Lundy, Jean E Russell, James A very etal: Effect of sodium fluoride on bone density in chickens. Calcif Tissue Int. 50:420-426, 1992.
41. Evans , F Wood JL : Mechanical properties and density of bone in a case of severe endemic fluorosis. Acta Orthop Scand 47:489-495,1976.
42. Rich C, Ensinck J: Effect of sodium fluoride on calcium metabolism of human beings. Nature 191:184-185,1961.
43. Briancon D, Meunier PJ: Treatment of osteoporosis with fluoride calcium and vitamin D. Orthop Clin North Am. 12:629-648,1981.
44. Lundy MW, Wergedal JE, Teubner E,etal: The effect of prolonged fluoride therapy for osteoporosis-bone composition and histology. Bone 10:321-327,1989.
45. Meunier PJ, Galus K , Braiancon D etal: Treatment of primary osteoporosis with drugs that increase bone formation: sodium fluoride, hPTH1-34, ADFR concept. In : Christiansen C, Arnaud C, Nordin BEC, Parffitt AM, Peck W, Tiggs BL. (eds) Glostrup Hospital Denmark 595-602, 1984.
46. Mamelle N, Menunier PJ, Dusan R, etal :Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 2:361-365, 1988.
47. BL Riggs, WM O'Fallon, A Lane etal: Clinical trial of fluoride thera-py in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 9(2):265-275, 1994.
48. Parffitt AM, Kleerekoper M, Villanueva AR: Increased bone age: mechanism and consequences In: Osteoporosis Eds: Christiansen C, Jo- hansen C, Riss BJ:Osteopress APS Copenhagen, 1987:301-308
49. Harrison JE, McNeill KG,Sturtridge WC, etal: Three-year changes in bone mineral mass of postmenopausal osteoporotic patients based on neutron activation analysis of the central third of the skeleton J Clin En- docrinol Metab. 52:751-758,1981.
50. Christopher W Marx, George E, Dailey S Carol Cheney etal: Do estrogens improve bone mineral density in osteoporotic women over age 65? J Bone Miner Res. 7(11) : 1275-1279,1992.
51.Riggs BL, Seeman E, Hodgson SF etal: Effect of the fluoride/calcium regimen on vertebral fracture occurrance in postmenopausal women: comparison with conventional therapy. N Engl J Med 306: 446-450, 1982.
52. Pak CYC, Sakhaee K, Gallegher C, etal: Attainment of therapeatic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis J Bone Miner Res 1: 563-71, 1986.
53.Muller P, simon B, Schmid K etal: Gastric effects of sodium fluoride: comparison with sodium monofluorophosphate. Bone Miner 17:(Suppl 1):1165,1992.
54. Boivin G, Gronsson B, Meunier PJ: X-ray raieroanalysis of fluoride distribution in microfracture calluses in cancellous iliac bone from osteoporotic patients treated with fluoride and untreated. J Bone Miner Res. 11:1183-90,1991.
55. GR Mundy; Visions for the future in osteoporosis research. Osteoporosis Int Suppl 2:s29-34,1993.
56. JD Ringe and PJ Meunier : What is the future for fluoride in the treatment of osteoporosis. Osteoporosis Int. 5.71-74, 1995.
57. Heaney RL : fluoride and osteoporosis. Ann Intern Med. 120:689-90, 1994.
1. Kodama H , Nose M ,etal: Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med. 173:1291-1294,1991.
2. Liggett W Jr, N Shevde, P Anklesaria et al: Effects of macrophage colony stimulating factor and granulocyte-macrophages colony stimulating factor on osteoclastic differentiation of hematopoietic progenitor cells. Stem cell (Dayt) 1993. Sep 11 (5):398-411.
3. Yoshida H, Hayashi S, etal: The murine mutation osteopetrosis is in the coding region of the macrophage colony-stimulating factor gene. Nature 345:442-445, 1990
4. Kodama H, Yamasaki A etal: Congenital osteoclast deficiency in os- teopetrotic (op/op) mice is cured by injections of macrophage colony- stimulating factor. J Exp Med. 173:269-273, 1991.
5. Tomio Morohashi, Veronique, Antonioli Corboz, V etal: Macrophage colony-stimulating factor restores bone resorption in op/op bone in vitro in conjunction with parathyroid hormone or 1,25-dihydroxyvitamin D_3 J Bone Miner Res 9(3) :401-407, 1994.
6. Antonioli Corboz V , Cecchini MG, etal: Effect of macrophage colony- stimulating factor on in vitro osteoclast generation and bone resorption. Endocrinology 130:437-442, 1992.
7. Tanaka S, Takahashi N, etal: Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 91:257-263, 1993.
8. Cecchini MG, Wetterwald A , etal: M-CSF acts on premitotic osteoclast progenitor, but is not necessary for short term (1 week) activity and survival of the mature osteoclasts. J Bone Miner Res 7 (Suppl. 1):S128 abstract 144, 1992.
9. Hattersley G, Chambers TJ: Generation of osteoclasts from hemopoietic cells and a multipotential cell line in vitro. J Cell Physiol 140:478-482, 1989.
10. Kurihara N, Suda T, etal: Generation of osteoclasts from isolated hematopoietic progenitor cell. Blood 74:1295-1302, 1989.
11. Sato T , Hong MH , etal: The specific production of the 3rd componentof complement by osteoblastic cells treated with 1 alpha, 25- dihydrox- yvitamin D_3. FEBS, Lett 285-21-24,1991
12. Hong MH, Jin CH, etal: Transcriptional regulation of the production of the third component of complement (C3) by 1 alpha, 25-dihydrox- yvitamin D_3 in mouse marrow-derived stromal cells (ST_2) and primary osteoblastic cells. Endocrinology 129.2774-2779, 1991.
13. Scheven BAA, Hamitton NJ, etal: osteoclast growth factor activity in medium conditioned by fetal rat bones. Bone Miner. 14: 221-235, 1991.
14. Oppeheim JJ, Kovacs EJ, etal: There is more than one interleukin. Immunol Today 7:45-56,1986.
15. Gowen M, Word DD, etal: Interleukin-1-like factor stimulates bone resorption in vitro. Nature 306:378-380, 1993.
16. Stashenko P, Dewhirst FE, etal: synergistic interactions between in- terleukin-1 tumor necrosis factor and lymphotoxin in bone resorption. J Immunol 138:1464-1468, 1987.
17. Kdning A, Muhlbauer RC, etal: Tumor necrosis factor a and inter- leukin-1 stimulate bone resorption in vivo as measured by urinary[~3H] tetracycline excretion from prelabeled mice. J Bone Miner Res 3 : 621- 627, 1988.
18. Boyce BF, Aufdemorte TB, etal: Effects of interleUkin-1 on bone turnover in normal mice. Endocrinology 125-1142-1150, 1989.
19. Boyce BF, Yates AJP etal: Bolus injections of recombinant human in- terleukin-1 cause transient hypocalcemia in normal mice. Endocrinology 125.2780-2783. 1989.
20. Garrett IR, Guise TA, etal: Evidence that interleukin-1 mediates its effects on bone resorption via the 80 kilodalton interleukin-1 receptor. Calcif Tissue Int 52:438-441, 1993.
21. Pfeilschifiter JP, Seyedin S, etal: Fransformed growth factor β inhibits bone resorption in fetal rat long bone cultures. J Clin Invest 82:680- 685, 1988.
22. Thomson BM, Saklatvala J, etal: Osteoblasts mediates interleukin-1 stimulation of bone resorption by rat osteoclasts. J, Exp Med. 164 - 104-112. 1986.
23. Sabatini M , Boyce B, etal: Infusion of recombinant human interleukin- 1α and β cause hypercalcemia in normal mice. Pro Natl Acad Sci U.S. A. 85:5235-5239, 1988.
24. Boyce BF, Aufdemorte TB, etal: Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 123:1142-1150, 1989.
25. Pacifici R, Rifas L, etal: Ovarian steriod treatment blocks a post- menopausal increase in blood monocyte interleukin-1 release. Pro Natl Acad Sci U.S. A. 86:2398-2402,1989.
26. Mundy GR: Malignancy and hypercalcemia:humoral hypercalcemia of malignancy, hyercalcemia associated with osteolytic metastases. In: Calcium homeostasis : hypercalcemia and hypocalcemia. London Martin Dunitz 69-99, 1990.
27. Alexander HK, Doherty GM etal: Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery 112:188-94, 1992.
28. Matti SG, Linner KM etal: Interleukin-1α and interleukin-1β stimulate adrenocorticotropin secretion in rats through similar hypothalamic receptor (s ): effect of interleukin-1 receptor antagonist protein. Neu- roendocrinology 57:14-22, 1993.
29. Petitelerc E , Abel S, et al: Effects of interleukin-1 receptor antagonist on three types of responses to interleukin in rabbit isolated blood vessels J. Cardiovasc Pharmacol. 19:821-829, 1992.
30. Sekinger P, Klein-Hulend J, etal: Natural and recombinant human IL- 1 receptor antagonist block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 145:4181-4183, 1990
31. Guise TA. Garrett IR, etal: Interleukin-1 receptor antagonist inhibits hypercalcemia mediated by interleukin-1. J Bone Miner Res 8:583- 587, 1993.
32. Kimble RB, Vannice JL etal: Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest. 93:1959-1967, 1994.
33. Bertoline PK , Nedwin GE , etal: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 319:5l6-518, 1986.
34. Johnson RA, Boyce BF, etal: Tumors producing human TNF induce hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology 124:1424-1427, 1989.
35. Thomson BM , Mundy GR, etal: Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulates osteoclastic bone resorption. J Immunol 138 : 775-779, 1989.
36. Garrett IR, Durie BGM, etal: Production of the bone resorbing cy- tokine lymphotoxin by cultured human myeloma cells. N Engl J Med 317:526-532, 1987.
37. Tashjian AH, Jr. Veelkel EF, etal: Tumor necrosis factor-alpha ( cachectin ) stimulates bone receptor in mouse calvaria via prostaglandin-medi ated mechanism. Endocrinology 120: 2029-2036, 1987.
38. Ibbotson KJ, Twardzrk DR, etal: Stimulation of bone resorption in vitro by synthetic transfoming growth factor alpha. Science 228:1007- 1009, 1985.
39. Yate AJP, Favarata G etal: Expression of human transforming growth factor a by Chinese hamster ovarian tumors in nude mice cause hypercalcemia and increased osteoclast bone resorption J Bone Miner Res 7: 847-853, 1992.
40. Takahahi N, MacDonald BR, etal: Recombinant human transforming growth factor alpha stimulates the formation of osteoclast-like cells in long-term human marrow cultures. J Clin Invest 78:894-898, 1986.
41. Lowik CWGM, Van der Plujm G, etal: Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by os- teogenic cell: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 162:1546-1552, 1989.
42. Kurihara N , Bertolini D, Suda T , etal: Interleukin-6 stimulates osteoclast-like multinucleated cell formation in long-term human marrow culture by inducing IL-1 release. J Immunol 144:426-430, 1990.
43. Linkhart TA, Linkhart SG, etal: Interleukin-6 messenger RNA expression and interleukin-6 protein secretion in normal human os-teoblast-like cells: Regulation by interleukin-1. J Bone Miner Res. 6: 1285-1294, 1991.
44. Roodman GD, Kurihara N, etal: Interleukin-6: a potential autocrine/ paracrine factor in Paget's disease of bone. J Clin Invest 89:46-52, 1991.
45. Ohsahi Y, Takahashi S, etal: Evidence for an autocrine/paracrine role for IL-6 in bone resorption by giant cell tumors of bone. Endocrinology 131:2229-2234,1992.
46. Black K , Garrett IR, Mnndy GR : Chinese hamster ovarian cells trans- fected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology 128:2657-2659,1991.
47. Poli V , Balena R, etal: Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:1189-1196, 1994.
48. Jilka RL, Hongoc G, etal: Increased osteoclast development after estrogen loss: mediation by Interleukin-6. Science 257:88-91, 1992.
49. Takahashi N, Mundy GR etal: Osteoclast like formation in fetal and newborn long term baboon marrow cultures is more sensitive to 1. 25- dihydroxyvitamin D_3 than adult long term marrow cultures. J Bone Miner Res 2:311-317, 1987.
50. Takahashi N, Mundy GR , Roodman GD: Recombinant human gamma interferon inhibits formation of osteoclast-like cells by inhibiting fusion of their precursor. J Immunol 137-3544-3549, 1986.
51. Gowen M, Mundy GR. Actions of recombinant interleukin-1 inter- lenkin-2 and interferon gamma on bone resorption in vitro J Immunol 136:2478-2482, 1986
52. Pfeilschifiter JP, Seyedin S, Mundy GR: Transformed growth factor-P inhibits bone resorption in fetal rat long bone cultures J Clin Invest 82: 680-685,1988.
53. Chena C, Pfeilschifiter JP, Mundy GR, etal: Transforming growth factor-p inhibits formation of osteoclast-like cells in long term human marrow cultures. Proc Natl Acad Sci USA 85:5683-5687, 1988.
54. Doron M Shinar and Gigeon A Rodan : Biphasic effects of transforming growth factor-β on the production of osteoclast-like cells in mouse bone marrow cultures : The role of prostaglandins in the generation of these cells. Endocrinology 126:3153-3158 1990
55. Howard M, Farrar J, et al: Identificatin of a T cell derived B cell growth factor distinct from interleukin 2. J Exp Med 155: 914-923, 1982.
56. Noma Y, Sideras P et al: Cloning of cDNA encoding the murine IgG_1 induction factor by novel strategy using SP_6 promoter. Nature 319: 640-646, 1986
57. Shioi A, Teitelbaum SL etal: Interleukin 4 inhibits murine osteoclast formation in vitro J Cell Biochem 47:272-277, 1991.
58. Watanabe K, Tanaka Y et al: Interleukin-4 as a potent inhibitor of bone resorption. Biochem Biophys Res Comm 172:1035-1041, 1990.
59. Yoichiro Nakano, Kenichi Watanabe etal: Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice. J Bone Miner Res 9(10): 1533-1539, 1994.
60. Essner R, Rhoades K, etal: IL-4 down regulates IL-1 and TNF gene expression in human monocytes. J Immunol 142:3857-3861, 1989.
61. Hart PH, Vitti GF etal: Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor a. interleukin 1 and prostaglandin E2. Pro Natl Acad Sci USA. 86-3803- 3807, 1989.
62. Miossec P, Briolay J etal: Inhibition of IL-6 production by IL-4. Calcif Tissue Int 46 (Suppl. 2):A 42 (abstract 163), 1990.
63. Takahashi N , Akatsu T, etal: osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600-2603, 1988.
64. Lacey DL , Erdmann JM etal: MC 3T3-EL osteoblastic cell express receptors for and responed to interleukin-4 J Bone Miner Res 6 (suppl. l):s225(abstract 686),1991.
65. Ueno K , Katayama T , etal: Interleukin 4 enhances in vitro mineralization in human ostesblast-like cells. Biochem Biophys Res Commun 189:1521-1526,1992.
66. Riancho JA , Zarrabeitia MT , etal: Effects of interleukin-4. on human osteoblast-like cells. Bone Miner 21 :53-61,1993.
67. Lawis DB, Liggit D etal: Mechanism of osteoporosis in IL-4 transgenic mice. J Bone Miner Res 7 (Suppl 1):S96 (abstract 15), 1992.
68. Gay CV: Osteoclast ultrastructure and enzyme histochemistry: Func-tional implications. In Rifkin BR. Gay CV(eds) Biology and physiology of the osteoclast. CRC press. Ann Arbor MI PP 129-150, 1992.
69. Anderson RE, Schraer H, Gay CV: Ultrastructural immunocy- tochemical localization of carbonic anhydrase in normal and calcitonin treated chick osteoclasts. Anat Rec 204:9-20, 1982.
70. Cao H, Gay CV : Effects of parathyroid hormone and calcitonin on carbonic anhydrase location in osteoclasts of culture embryonic chick bone. Experentia 41:1472-1474, 1985.
71. Zheng MG, Fan Y etal: Detection of carbonic anhydrase I in human osteoclast-like cells by in situ hybridization. J Bone Miner Res 8:113- 118, 1993.
72. Baron R, Neff L, etal: Evidence for a high and specific concentration of (Na~+,K~+ ) ATPase in the plasma membrane of osteoclast. Cell. 46:311,1986.
73. Reggio H, Bainton D, etal: Antibodies against lysosomal membranes reveal a 100,000-mol-wt protein that cross reacts with purified H~+ K~+ ATPase from gastric mucosa. J Cell Biol 99:1511, 1984.
74. Laitala T Vaananen K; Proton channel part of vacuolar H~+-ATPase and carbonic anhydrase I expression is stimulated in resorbing osteoclasts J Bone miner Res 8:119-126, 1993.
75. S Asotra, A.K Gupta etal: Carbonic anhydrase I mRNA expression in individual osteoclasts. Under "Resorbing" and "Non resorbing" conditions. J Bone Miner Res. 9(7): 1115-1122, 1994
76. MH Zheng, T-T. A lau etal: 173-estradiol suppresses gene expression of tartrate-resistant acid phosphatase and carbonic anhydrase I in o- variectomized rats. Calcif Tissue Int. 56:166-169, 1995.
77. Horton MA : Osteoclast-specific antigens. ISI Atlas Sci Immunol 1:35- 43, 1988.
78. Horton MA, Davies J: Perspectives: Adhesion receptors in bone. J Bone Miner Res 4,803-809, 1989.
79. Albeda SM, Buck CA : Integrins and other cell adhesion molecules. FASEB J. 4:2826-2880, 1990.
80. Ruoslahti E : Integrins. J Clin Invest 87:1-5, 1991.
81. Gehron-Robey P: Calcified tissue matrix: composition and regulation.Workshop C American Society of Bone and Research meeting. Atlanta pp1-15, 1990.
82. Grzesik WJ, Robey PG : Bone matrix RGD-glycoproteins: immunolo-calization and interaction with primary cell in vitro. J Bone Miner Res. 9,487-496, 1994.
83. Kukreja SC, D' Anza JJ, etal: Effect of kistrin on serum calcium in normal and hypercalcemic mice. J Bone Miner Res 7(S129):148,1992.
84. Kathleen L. King, James. J. D' Anza etalj Effects of kistrin on bone resorption in vitro and serum calcium in vitro. J Bone Miner Res 9(3) : 381-387, 1994.
85. Maciewicz RA , Etherington DJ: A comparison of four cathepsins (B. L. N and S) with collagenolytic activity from rabbit spleen. Biochem J. 256:433-440,1988.
86.Rifkin BR, Vernillo AT, Kleckner AP et ah Cathepsin B and L activities in isolated osteoclasts. Biochem Biophys Res Commun 179:63-69, 1991.
87. Bailey AJ, Etherington DJ In:Florkin M. Stolz E(eds) Comprehensive Biochemistry. Elsevier/North Holland Biomedical Press, Amsterdam pp299-460, 1980
88. Burleigh MC, Barrett AJ, Lazarus GS: Cathepsin B: a lysosomal enzyme that degrades native collagen Biochem J. 137:387-398, 1974.
89. Karhukorpi EK, Vihko P, Vaananen K : A difference in the enzyme contents of resorption lacunae and secondary lysosomes of osteoclasts. Acta Histochem. 92:1-11, 1992.
90. Van Noorden CJF, Everts V: Selective inhibition of cysteine proteinas- es by Z-Phe-AlaCHZF suppresses digestion of collagen by fibroblasts and osteoclasts. Biochem Biophys Res Commun 178:178-184, 1991.
91. Wooley DE: Mammalian collagenase In :Piez KA, Reddi AH (eds) Extracellular Matrix Biochemistry. Elsevier New York pp. 119-157. 1984.
92. Sakamoto S, Sakamoto M: Immunocytochemical localization of collagenase in isolated mouse bone cells. Biomed Res 5:29-38, 1984.
93. Delaisse JM, Eeckhout Y, Vaes G: Bone-resorbing agents affect the production and distribution of procollagenase as well as the activity of??collagenase in bone tissue. Endocrinology 123:264-276, 1988.
94. Partridge NC, Jeffrey JJ, Ehlich LS, etal: Hormonal regulation of the production of collagenase and of a collagenase inhibitor activity by rat osteogenic sarcoma cells. Endocrinology 120:1956-1962, 1987.
95. Jilka RL: Procollagenase associated with the noncalcified matrix of bone and its regulation by parathyroid hormone. Bone 10:353-358, 1989.
96. Delaisse JM , Eeckhout Y, Sear C, etal: A new synthetic inhibitor fo mammalian tissue collagenase inhibits bone resorption in culture. Biochem Biophy Res Commun 133:483-490,1985.
97. Chambers TJ, Fuller K : Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact J Cell Sci 76: 155- 165, 1985.
98. Chambers TJ, Darby JA, Fuller K : Mammalian collagenase predisposes bone surfaces to osteoclastic resorption. Cell Tissue Res. 241 : 671- 675, 1985.
99. Soriano P, Montgomery C etal: Targeted disruption of the c-src proto- oncogene lead to osteopetrosis in mice. Cell 64:693-697, 1991.
100.Kato I, Yoneda T etal: Osteoclasts deficiency in c-src tyrosine kinase fail to resorb bone in vitro and in vivo. J Bone Miner Res 6:(suppl): abstr 452, 1991.
2. Robert Lindsay: Fluoride and bone-quantity versus quality. N Engl J Med 322 (12):845-846, 1990.
3. Melton LJ, Kan SH, Frye MA, etal: Epidemiology of vertebral fractures in women. American Joumal of Epidemiology. 129:1000-1011, 1989.
4. Cummings SR , Kelsey JL, Nevitt MC, etal: Epidemiology of osteoporosis and os- teoporotic fractures. Epidemiological Reviews 7:178-208, 1985.
5. L Joseph Melton III : How much women have osteoporosis now? J Bone Miner Res 10(2),175-177, 1995.
6.TJ Martin, Kong Wah Ng, Tatsuo Suda: Bone cell physiology. Endocrinology and Metabolism Clinics of North America 18(4): 833-857, 1989.
7.M Arlot, C Edouard, PJ Meunier etal: Impaired osteoblast function in osteoporosis : comparison between calcium balance and dynamic histomorphometry. British Medical Journal 289:517-520, 1984.
8. Lundy M W, Wergedal JE, Teubner E, etal : The effect of prolonged fluoride therapy for osteoporosis bone composition and histology. Bone 10.321-327, 1989.
9. Kleerekoper M, Peterson EL, Nelson DA etal: A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1:155-161, 1991.
10. Farley JR, Wergedal JE, Baylink DJ: Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone forming cells. Science 222:330-332, 1983.
11. Moustapha kassem, Leif Mosekilde, and Erik Fink Eriksen: 1,25-Dihydroxyvi-tamin D_3 potentiation fluoride stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cells. J Bone Miner Res 8(12) : 1453-1458, 1993.
12. Riggs BL , Hodgson SF, O' Falion WM , etal: Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809, 1990.
13. MW Lundy, M Stauffer, JE Wergedal etal: Histomorphometric analysis of iliac crest bone biopsies in placebo-treated versus fluoride-treated subjects. Osteoporosis Int 5:115-129, 1995.
14. N Mamelle, PJ Meunier R Dusan etal: Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 2:361-365, 1988
15. BL Riggs, WM O' Fallon, A Lane etal: Clinical trial of fluoride therapy in post-??menopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 9(2):265-275, 1994.
16. Helmut Reichel, H Phillip Koeffler, and Anthony W Norman: The role of the vitamin D endocrine system in health and disease. N Engl J Med 320(15):980-991, 1989.
17. Marie-claude Faugere, Sumiaki Okamoto, Hector F Deluca: Calcitroil corrects bone loss induced by oophorectomy in rats. Am J physiol 250:E35-E38, 1986.
18. Kleerekoper M , Balena R: Fluoride and ostooporosis Annu Rev Nutr 11:309-324, 1991.
19.Fleish H: Bisphosphonates. Drugs 42:919-44, 1991.
20. Kanis JA: Pathophysiology and treatment of Paget's disease of bone London: Martin Dunitz 1991.
21. Russell RGG, Kanis JA: Tumor-induced hypercalccmia and its management. Royal Society of Medicine International Congress and Symposium Series 176 London: RSM 1991.
22. Tommy Sterm, Torben Steiniche, Gorm Thamsborg etal: Changes in bone histo-mophometry after Long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8(2):199-208, 1993.
23. Erik Fink Eriksen, Torben Steiniche, Leif Mosekilde etal: Histomorphometric analysis of bone in metabolic bone disease. Endocrinology and Metabslism Clinics of North American 18(4):919-954, 1989.
24. P Fratzl, P Roschger, J Eschberger etal: Abnormal bone mineralization after fluoride treatment in osteoporosis: A small angle X-ray-scattering study J Bone Miner Res 9(10):1541-1549, 1994.
25. Etsuji Shiota: Effects of diphosphonate on osteoporosis induced in rats, roen-togenological, histological and biomechanical studies. Fukuoka Acta Med 76(6): 317-342, 1985.
26. Roland Baron, Agnes Vignery, Lynn Neff etal: Processing of undecalcified bone specimens for bone histomophometry. In Recker RR (ed): Bone histomor-phometry techniques and interpretation. Boca Raton Florida CRC Press Inc 1983 pl4-30
27.XJ Li, WSS Jee, HZ ke, etal: Age-related changes of cancellous and cortical bone histomorphometry in female Sprague-Dawley rats. Cell and Material (Suppl) l: 25, 1991.
28. Takashi Katsumata, Toshitaka Nakamura, Hideo Ohnishi etal: Intermittent Cyclical etidronate treatment maintain the mass, structure and mechanical property of bone in ovariectomized rats. J Bone Miner Res 10(6) : 921-931, 1995.29．王以进，王介麟编著 骨科生物力学。北京：人民军医出版社1989
30．孟迅吾，刑小平，陈莉等：血清抗酒石酸酸性磷酸酶浓度测定的初步临床应用．中华内分泌代谢杂志11(1)：9-11，1995
31. GR Mundy: Visions for the future in osteoporosis research. Osteoporosis Int (Suppl) 2: s29-34, 1993
32. TJ Wronski and CF Yen: The ovariectomized rat as an animal model for postmenopausal bone loss. Cell and Material (suppl) 1: 69-74, 1991.
33. Frost HM and WSS Jee: On the rat model of human osteopenias and osteoporosis Bone Miner 18: 227-236, 1992.
34. Mosekilde Li and Sgaard CH: Assessing bone quality. The International Conference on Animal Models in the Prevention and Treatment of Osteopenia (Abstract) 1995, p1
35. DD Thompson: Animal models and the FDA guidelines for osteoporosis. The International Conference on Animal Models in the Prevention and Treatment of Osteopenia (Abstract) 1995, p1
36. Kalu DN: The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15: 175-192, 1991.
37. TJ Wronski, PLLowry, CC Walsh et al: Skeletal alteration in ovariectomized rats. Calcif Tissue Int. 37: 324-328, 1985.
38. JD Ringe and PJ Meunier: What is the future for fluoride in the treatment of osteoporosis? Osteoporosis Int 5: 71-74, 1995.
39. Pascale Chavassieux, Chantal Chenu, Alexandre Valentin-Opran et al: In vitro exposure to sodium fluoride does not modify activity or proliferation of human osteoblastic cells in primary cultures. J Bone Miner Res 8(1): 37-45, 1993.
40. Robert P, Heaney David J Baylink, C Conrad Johnston, Jr et al: Fluoride therapy for the vertebral crush fracture syndrome. A status report. Annals of Internal Medicine 111(8): 678-680, 1989.
41. R Hall, G Embery, R Waddington et al: The influence of fluoride on the adsorption of proteoglycans and glycosaminoglycans to hydroxyapatite. Caleif Tissue Int. 56: 236-239, 1995.
42. Beresford JN, Gallagher JA, Poser JW, et al: Production of osteocalcin by human bone cells in vitro effects of 1α25 (OH)_2D_3 parathyroid hormone and glueocorticoids. Metab Bone Dis 5: 229-235, 1984
43. Price PA, Baukol SA: 1,25-Dihydroxyvitamin D_3 increases synthesis of the vitamin k-dependent bone protein by osteosarcoma cells J Biol chem 255: 11660-11663, 1980.
44. Chenu C, Valentin-Operan A, Chavassieux P, et al: Insulin-like growth factor I??(IGF-I) hormonal regulation by growth hormoneand 1,25(OH)_2D_3, and activity on human osteoblast-like cells in short-term cultures. Bone 11:81-86, 1990.
45. Petkovich PM, Wrana JL, Grigoriadis AE etal: 1, 25-dihydroxyvitamin D_(?) increases epidermal growth factor receptors and transforming growth factor β-like activity in a bone-derived cell line J Biol Chem 262:13424-8, 1987.
46. Berenice Y Reed, Joseph E Zerwekh, Peter P Antich etal: Fluoride-stimulated [~3H] thymidine uptake in a human osteoblastic osteosarcoma cell line is dependent on transforming growth factor β. J Bone Miner Res 8(1): 19-25, 1993.
47. Dempster DW, Li X-F, Birchmaan RV, Shen R etal: On the mechanism of can-cellous bone loss in the ovariectomized rat. Bone Miner 17:s29, 1992.
48. DB Lauritzen, R Balzna, M Shea etal: Effect of combinated prostaglandin and Al-endronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats. J Bone Miner Res 8(7):871-879, 1993
49. Pierre J Marie and Monique Hott: Short-term effects of fluoride and strontium on bone formation and resorption in the mouse. Metabolism 35(6) :547-551, 1986.
50. Briancon D, Meunier PJ: Treatment of osteoporosis with fluoride, calcium and vitamin D. Orthop Clin North AM 12:629-648, 1981.
51. Sahni M , Guenther HL, Fleisch H, etal: Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004-11, 1993.
52. Stronski SA, L Bettschen-Camin, A Wetterwald etal: Bisphosphonates inhibit 1, 25-dihydroxyvitamin D_3-induced increase of osteocalcin in plasma of rats in vivo and in culture medium. Calcif Tissue Int 42:248-254, 1988.
53. Ohya K , S Yamada, R Felix etal: Effect of bisphosphonates on prostaglandin synthesis by rat bone cells and mouse calvaria in culture. Clin Sci (Lond) 69:403-411, 1985.
54. Lenehan TM, Balligand M, Nunamaker DM, etal: Effects of EHDP on fracture healing in dogs. J Orthop Res 3:499-507, 1985
55. Flora L, Hassing GS, Parfitt AM etal: Comparative skeletal effects of two diphosphonates in dogs. Metab Bone Dis Rel Res 2:389-407, 1980.
56. Dominique Modrowski, Livia Miravet, Michel Feuga etal: Effect of fluoride on bone and bone cells in ovariectomized rats. J Bone Miner Res 7(8): 961-969, 1992.1. Consensus development conference Prophylaxis and treatment of osteoporosis. Am L Med 90: 107-110, 1991
2. Robert Lindsay: Fluoride and bone-quantity versus quality. N Eng1 J Med 322(12):845-846, 1991
3. Melton LJ, Kan SH, Frye MA, etal: Epidemiology of vertebral fractures in women. American Journal of Epidemiology 129:1000-1011, 1989.
4. Cummings SR, kelsey JL , Nevitt MC, etal: Epidemiology of osteoporosis and osteoporotic fractures. Epidemiological Reviews 7: 178-208, 1985.
5. L. Joseph Melton III : How much women have osteoporosis now? J Bone Miner Res 10(2) : 175-177, 1995.
6. Riggs BL, Hodgson SF, O' Fallon WM etal: Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809, 1990.
7. Kleerekoper M, Peterson EL, Nelson DA etal: A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int. 1:155-161, 1991.
8. Pierre J. Marie and Monique Hott: Short-term effects of fluoride and strontium on bone formation and resorption in the mouse. Metabolism. 35(6).547-551, 1986.
9. Gillian R Show and C Anderson: Short-term chronic fluoride administration and trabecular bone remodeling in beagles: A polit study. Calcif Tissue Int 38:217-221, 1986.
10. Dominique Modrowski, Livia Miravet etal: Effect of fluoride on bone and bone cell in ovariectomized rat. J Bone Miner Res 7(8): 961-969, 1992.
11. J Kragstrag , Richards A , Fejerskov etal: Experimental osteo-fluorosis in the domestic pig A histomorphometric study of vertebral trabecular bone. J Dent Res 63(6):885-889 June. 1984.
12. Aaron JE, De vernejoul MC, Kanis JA: The effect of sodium fluoride on trabecular architecture. Bone. 12:307-310,1991.
13. Lafage MH ,Balena R, etal: Comparison of alendronate and sodium flu-oride effects in minipigs : one year study. Calcif Tissue Int. 52 (Suppl 1):s96,1993.
14. Thomas A Einhorn, GK Wakey, etal: Incorporation of sodium fluoride into cortical bone does not impair the mechanical properties of the ap- pendicular skeleton in rat. Calcif Tissue Int. 51:127-131,1992.
15. MW Lundy, M Stauffer etal: Histomorpometric analysis of iliac crest bone biopsies in placebo-treated versus fluoride-treated subjects. Osteoporosis Int 5:115-129,1995.
16. Hall BK : Sodium fluoride as an initiator of osteogenesis from embryonic mesenchyme in vitro. Bone 8:111-116, 1987.
17. Farley JR, Wergedal JE , Baylink DJ: Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone forming cells. Science 223:330-332, 1983.
18. Farley JR, Nanine Tarbaux, Susan Hall etal: Evidence that fluoride-stimulated ~3[H]-thymidine incorporation in embryonic chick calvarial cultures is dependent on the presence of a bone cell mitogen sensitive to changes in the phosphate concentration and modulated by systemic skeletal effectors. Metabolism 37:988-995, 1988.
19.BY Reed, Joseph E Zerwekh, Peter D Autich etal: Fluoride-stimulated ~3[h] thymidine uptake in a human osteoblastic osteosarcoma cell line is dependent on transforming growth factor β. J Bone Miner Res 8(1) : 19-25, 1993
20. M Kassem , Leif Mosekilde and Erik Fink Eriksen: 1,25-dihydroxyvi- tamin D_3 potentiates fluoride-stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cells. J Bone Miner Res 8(12) : 1453-1458,1993.
21. Pascale chavassieux, Chantal Chenu, Alexandre Valentin-Opran etal: In vitro exposure to sodium fluoride does not modify activity or proliferation of human osteoblastic cells in primary cultures. J Bone Miner Res. 8(1),37-44,1993.
22. Marie PJ, De. Vernejoul MC, Lomri A : Stimulation of bone formation in osteoporosis patients treated with fluoride associated with increased DNA synthesis by osteoblastic cells in vitro J Bone Miner Res. 7:103- 113, 1992.
23. Farley JR, Tarbaux N , Hell S,etal: Mitogenic action (s) of fluoride on osteoblast-like cells:Determinants of the response in vitro J Bone Miner Res. 5:s107-s113, 1990.
24. Gruber HE, Baylink DJ: The effects of fluoride on bone. Clin Orthop Rel Res 267: 264-277, 1991.
25. Lau KHW, Farley JR, Freeman TK, etal: A proposed mechanism of the mitogenic action of fluoride on bone cells :inhibition of activity of an osteoblastic acid phosphatase. Metabolism 38:858-868,1989.
26. D Burgener, J-P Bonjour and J Caverzasio: Fluoride increase tyrosine kinase activity in osteoblast-like cell :regulatory role for the stimulation of cell proliferation and Pi transport across the plasma membrane. J Bone Miner Res. 10(1) : 164-171,1995.
27. Kato I Yoneda T, etal:Osteoclasts deficiency in c-src tyrosine kinase fail to resorb bone in vitro and in vivo. J Bone Miner Res 6:[Suppl]:ab- str 452,1991.
28. Dziewiatowski DD: Binding of calcium by proteoglycans in vitro. Calcif Tissue Int. 40:265-269,1987.
29. Templeton DM : Metal binding properties of the isolated glomerular basement membrane. Biochim Biophys Acta 926:94-105,1987.
30. Fujisawa R, Kuboki Y: Preferential adsorption of dentine and bone acidic proteins on the (100) face of hydroxyapatite crystals. Biochim Biophys Acta. 1075:56-60, 1991.
31. Smalley JW, Embery G: The influence of fluoride administration on the structure of proteoglycans in the developing rat incisor. Biochem J. 190:263-272,1980.
32. Waddington RJ, Embery G etal: The influence of fluoride on proteo- glycan structure using a rat odontoblast in vitro system. Calcif Tissue Int. 52:392-398, 1993.
33. Susheela AK , Sharma K,etal: The status of sulfated isomers of gly- cosaminoglycans in fluorosed human teeth. Archs Oral Biol 33:765-767, 1988.
34. Susheela AK , Mukergee D: Fluoride poisoning and the effect on collagen biosynthesis of osseous and non osseous tissue of rabbit. Toxicol Eur Res. 2:99-104, 1981.
35. Sharma. YD: Effect of sodium fluoride on collagen cross-link precursors. Toxicol Lett 10:97-100,1982.
36. Sharma YD: Variations in the metabolism and maturation of collagen after fluoride ingestion. Biochim Biophys Acta 715:137-141,1982.
37. Embery G, Rolla G, etal: Interaction of acidic glycosaminoglycans (mucopolysaccharides) with hydroxyapatite. Scand J Dent Res 23-13- 17,1979.
38. R Hall, G Embery etal : The influence of fluoride on the adsorption of proteoglycans and glycosaminoglycans to hydroxyapatite. Calcif Tissue Int. 56.236-239,1995.
39. P Fratzl, P Roschger etal: Abnormal bone mineralization after fluoride treatment in osteoporosis:A small-angle x-ray-scattering study. J Bone and Miner Res. 9(10) : 1541-1549,1994.
40. Mark W Lundy, Jean E Russell, James A very etal: Effect of sodium fluoride on bone density in chickens. Calcif Tissue Int. 50:420-426, 1992.
41. Evans , F Wood JL : Mechanical properties and density of bone in a case of severe endemic fluorosis. Acta Orthop Scand 47:489-495,1976.
42. Rich C, Ensinck J: Effect of sodium fluoride on calcium metabolism of human beings. Nature 191:184-185,1961.
43. Briancon D, Meunier PJ: Treatment of osteoporosis with fluoride calcium and vitamin D. Orthop Clin North Am. 12:629-648,1981.
44. Lundy MW, Wergedal JE, Teubner E,etal: The effect of prolonged fluoride therapy for osteoporosis-bone composition and histology. Bone 10:321-327,1989.
45. Meunier PJ, Galus K , Braiancon D etal: Treatment of primary osteoporosis with drugs that increase bone formation: sodium fluoride, hPTH1-34, ADFR concept. In : Christiansen C, Arnaud C, Nordin BEC, Parffitt AM, Peck W, Tiggs BL. (eds) Glostrup Hospital Denmark 595-602, 1984.
46. Mamelle N, Menunier PJ, Dusan R, etal :Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 2:361-365, 1988.
47. BL Riggs, WM O'Fallon, A Lane etal: Clinical trial of fluoride thera-py in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 9(2):265-275, 1994.
48. Parffitt AM, Kleerekoper M, Villanueva AR: Increased bone age: mechanism and consequences In: Osteoporosis Eds: Christiansen C, Jo- hansen C, Riss BJ:Osteopress APS Copenhagen, 1987:301-308
49. Harrison JE, McNeill KG,Sturtridge WC, etal: Three-year changes in bone mineral mass of postmenopausal osteoporotic patients based on neutron activation analysis of the central third of the skeleton J Clin En- docrinol Metab. 52:751-758,1981.
50. Christopher W Marx, George E, Dailey S Carol Cheney etal: Do estrogens improve bone mineral density in osteoporotic women over age 65? J Bone Miner Res. 7(11) : 1275-1279,1992.
51.Riggs BL, Seeman E, Hodgson SF etal: Effect of the fluoride/calcium regimen on vertebral fracture occurrance in postmenopausal women: comparison with conventional therapy. N Engl J Med 306: 446-450, 1982.
52. Pak CYC, Sakhaee K, Gallegher C, etal: Attainment of therapeatic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis J Bone Miner Res 1: 563-71, 1986.
53.Muller P, simon B, Schmid K etal: Gastric effects of sodium fluoride: comparison with sodium monofluorophosphate. Bone Miner 17:(Suppl 1):1165,1992.
54. Boivin G, Gronsson B, Meunier PJ: X-ray raieroanalysis of fluoride distribution in microfracture calluses in cancellous iliac bone from osteoporotic patients treated with fluoride and untreated. J Bone Miner Res. 11:1183-90,1991.
55. GR Mundy; Visions for the future in osteoporosis research. Osteoporosis Int Suppl 2:s29-34,1993.
56. JD Ringe and PJ Meunier : What is the future for fluoride in the treatment of osteoporosis. Osteoporosis Int. 5.71-74, 1995.
57. Heaney RL : fluoride and osteoporosis. Ann Intern Med. 120:689-90, 1994.
1. Kodama H , Nose M ,etal: Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med. 173:1291-1294,1991.
2. Liggett W Jr, N Shevde, P Anklesaria et al: Effects of macrophage colony stimulating factor and granulocyte-macrophages colony stimulating factor on osteoclastic differentiation of hematopoietic progenitor cells. Stem cell (Dayt) 1993. Sep 11 (5):398-411.
3. Yoshida H, Hayashi S, etal: The murine mutation osteopetrosis is in the coding region of the macrophage colony-stimulating factor gene. Nature 345:442-445, 1990
4. Kodama H, Yamasaki A etal: Congenital osteoclast deficiency in os- teopetrotic (op/op) mice is cured by injections of macrophage colony- stimulating factor. J Exp Med. 173:269-273, 1991.
5. Tomio Morohashi, Veronique, Antonioli Corboz, V etal: Macrophage colony-stimulating factor restores bone resorption in op/op bone in vitro in conjunction with parathyroid hormone or 1,25-dihydroxyvitamin D_3 J Bone Miner Res 9(3) :401-407, 1994.
6. Antonioli Corboz V , Cecchini MG, etal: Effect of macrophage colony- stimulating factor on in vitro osteoclast generation and bone resorption. Endocrinology 130:437-442, 1992.
7. Tanaka S, Takahashi N, etal: Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 91:257-263, 1993.
8. Cecchini MG, Wetterwald A , etal: M-CSF acts on premitotic osteoclast progenitor, but is not necessary for short term (1 week) activity and survival of the mature osteoclasts. J Bone Miner Res 7 (Suppl. 1):S128 abstract 144, 1992.
9. Hattersley G, Chambers TJ: Generation of osteoclasts from hemopoietic cells and a multipotential cell line in vitro. J Cell Physiol 140:478-482, 1989.
10. Kurihara N, Suda T, etal: Generation of osteoclasts from isolated hematopoietic progenitor cell. Blood 74:1295-1302, 1989.
11. Sato T , Hong MH , etal: The specific production of the 3rd componentof complement by osteoblastic cells treated with 1 alpha, 25- dihydrox- yvitamin D_3. FEBS, Lett 285-21-24,1991
12. Hong MH, Jin CH, etal: Transcriptional regulation of the production of the third component of complement (C3) by 1 alpha, 25-dihydrox- yvitamin D_3 in mouse marrow-derived stromal cells (ST_2) and primary osteoblastic cells. Endocrinology 129.2774-2779, 1991.
13. Scheven BAA, Hamitton NJ, etal: osteoclast growth factor activity in medium conditioned by fetal rat bones. Bone Miner. 14: 221-235, 1991.
14. Oppeheim JJ, Kovacs EJ, etal: There is more than one interleukin. Immunol Today 7:45-56,1986.
15. Gowen M, Word DD, etal: Interleukin-1-like factor stimulates bone resorption in vitro. Nature 306:378-380, 1993.
16. Stashenko P, Dewhirst FE, etal: synergistic interactions between in- terleukin-1 tumor necrosis factor and lymphotoxin in bone resorption. J Immunol 138:1464-1468, 1987.
17. Kdning A, Muhlbauer RC, etal: Tumor necrosis factor a and inter- leukin-1 stimulate bone resorption in vivo as measured by urinary[~3H] tetracycline excretion from prelabeled mice. J Bone Miner Res 3 : 621- 627, 1988.
18. Boyce BF, Aufdemorte TB, etal: Effects of interleUkin-1 on bone turnover in normal mice. Endocrinology 125-1142-1150, 1989.
19. Boyce BF, Yates AJP etal: Bolus injections of recombinant human in- terleukin-1 cause transient hypocalcemia in normal mice. Endocrinology 125.2780-2783. 1989.
20. Garrett IR, Guise TA, etal: Evidence that interleukin-1 mediates its effects on bone resorption via the 80 kilodalton interleukin-1 receptor. Calcif Tissue Int 52:438-441, 1993.
21. Pfeilschifiter JP, Seyedin S, etal: Fransformed growth factor β inhibits bone resorption in fetal rat long bone cultures. J Clin Invest 82:680- 685, 1988.
22. Thomson BM, Saklatvala J, etal: Osteoblasts mediates interleukin-1 stimulation of bone resorption by rat osteoclasts. J, Exp Med. 164 - 104-112. 1986.
23. Sabatini M , Boyce B, etal: Infusion of recombinant human interleukin- 1α and β cause hypercalcemia in normal mice. Pro Natl Acad Sci U.S. A. 85:5235-5239, 1988.
24. Boyce BF, Aufdemorte TB, etal: Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 123:1142-1150, 1989.
25. Pacifici R, Rifas L, etal: Ovarian steriod treatment blocks a post- menopausal increase in blood monocyte interleukin-1 release. Pro Natl Acad Sci U.S. A. 86:2398-2402,1989.
26. Mundy GR: Malignancy and hypercalcemia:humoral hypercalcemia of malignancy, hyercalcemia associated with osteolytic metastases. In: Calcium homeostasis : hypercalcemia and hypocalcemia. London Martin Dunitz 69-99, 1990.
27. Alexander HK, Doherty GM etal: Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery 112:188-94, 1992.
28. Matti SG, Linner KM etal: Interleukin-1α and interleukin-1β stimulate adrenocorticotropin secretion in rats through similar hypothalamic receptor (s ): effect of interleukin-1 receptor antagonist protein. Neu- roendocrinology 57:14-22, 1993.
29. Petitelerc E , Abel S, et al: Effects of interleukin-1 receptor antagonist on three types of responses to interleukin in rabbit isolated blood vessels J. Cardiovasc Pharmacol. 19:821-829, 1992.
30. Sekinger P, Klein-Hulend J, etal: Natural and recombinant human IL- 1 receptor antagonist block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 145:4181-4183, 1990
31. Guise TA. Garrett IR, etal: Interleukin-1 receptor antagonist inhibits hypercalcemia mediated by interleukin-1. J Bone Miner Res 8:583- 587, 1993.
32. Kimble RB, Vannice JL etal: Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest. 93:1959-1967, 1994.
33. Bertoline PK , Nedwin GE , etal: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 319:5l6-518, 1986.
34. Johnson RA, Boyce BF, etal: Tumors producing human TNF induce hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology 124:1424-1427, 1989.
35. Thomson BM , Mundy GR, etal: Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulates osteoclastic bone resorption. J Immunol 138 : 775-779, 1989.
36. Garrett IR, Durie BGM, etal: Production of the bone resorbing cy- tokine lymphotoxin by cultured human myeloma cells. N Engl J Med 317:526-532, 1987.
37. Tashjian AH, Jr. Veelkel EF, etal: Tumor necrosis factor-alpha ( cachectin ) stimulates bone receptor in mouse calvaria via prostaglandin-medi ated mechanism. Endocrinology 120: 2029-2036, 1987.
38. Ibbotson KJ, Twardzrk DR, etal: Stimulation of bone resorption in vitro by synthetic transfoming growth factor alpha. Science 228:1007- 1009, 1985.
39. Yate AJP, Favarata G etal: Expression of human transforming growth factor a by Chinese hamster ovarian tumors in nude mice cause hypercalcemia and increased osteoclast bone resorption J Bone Miner Res 7: 847-853, 1992.
40. Takahahi N, MacDonald BR, etal: Recombinant human transforming growth factor alpha stimulates the formation of osteoclast-like cells in long-term human marrow cultures. J Clin Invest 78:894-898, 1986.
41. Lowik CWGM, Van der Plujm G, etal: Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by os- teogenic cell: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 162:1546-1552, 1989.
42. Kurihara N , Bertolini D, Suda T , etal: Interleukin-6 stimulates osteoclast-like multinucleated cell formation in long-term human marrow culture by inducing IL-1 release. J Immunol 144:426-430, 1990.
43. Linkhart TA, Linkhart SG, etal: Interleukin-6 messenger RNA expression and interleukin-6 protein secretion in normal human os-teoblast-like cells: Regulation by interleukin-1. J Bone Miner Res. 6: 1285-1294, 1991.
44. Roodman GD, Kurihara N, etal: Interleukin-6: a potential autocrine/ paracrine factor in Paget's disease of bone. J Clin Invest 89:46-52, 1991.
45. Ohsahi Y, Takahashi S, etal: Evidence for an autocrine/paracrine role for IL-6 in bone resorption by giant cell tumors of bone. Endocrinology 131:2229-2234,1992.
46. Black K , Garrett IR, Mnndy GR : Chinese hamster ovarian cells trans- fected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology 128:2657-2659,1991.
47. Poli V , Balena R, etal: Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:1189-1196, 1994.
48. Jilka RL, Hongoc G, etal: Increased osteoclast development after estrogen loss: mediation by Interleukin-6. Science 257:88-91, 1992.
49. Takahashi N, Mundy GR etal: Osteoclast like formation in fetal and newborn long term baboon marrow cultures is more sensitive to 1. 25- dihydroxyvitamin D_3 than adult long term marrow cultures. J Bone Miner Res 2:311-317, 1987.
50. Takahashi N, Mundy GR , Roodman GD: Recombinant human gamma interferon inhibits formation of osteoclast-like cells by inhibiting fusion of their precursor. J Immunol 137-3544-3549, 1986.
51. Gowen M, Mundy GR. Actions of recombinant interleukin-1 inter- lenkin-2 and interferon gamma on bone resorption in vitro J Immunol 136:2478-2482, 1986
52. Pfeilschifiter JP, Seyedin S, Mundy GR: Transformed growth factor-P inhibits bone resorption in fetal rat long bone cultures J Clin Invest 82: 680-685,1988.
53. Chena C, Pfeilschifiter JP, Mundy GR, etal: Transforming growth factor-p inhibits formation of osteoclast-like cells in long term human marrow cultures. Proc Natl Acad Sci USA 85:5683-5687, 1988.
54. Doron M Shinar and Gigeon A Rodan : Biphasic effects of transforming growth factor-β on the production of osteoclast-like cells in mouse bone marrow cultures : The role of prostaglandins in the generation of these cells. Endocrinology 126:3153-3158 1990
55. Howard M, Farrar J, et al: Identificatin of a T cell derived B cell growth factor distinct from interleukin 2. J Exp Med 155: 914-923, 1982.
56. Noma Y, Sideras P et al: Cloning of cDNA encoding the murine IgG_1 induction factor by novel strategy using SP_6 promoter. Nature 319: 640-646, 1986
57. Shioi A, Teitelbaum SL etal: Interleukin 4 inhibits murine osteoclast formation in vitro J Cell Biochem 47:272-277, 1991.
58. Watanabe K, Tanaka Y et al: Interleukin-4 as a potent inhibitor of bone resorption. Biochem Biophys Res Comm 172:1035-1041, 1990.
59. Yoichiro Nakano, Kenichi Watanabe etal: Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice. J Bone Miner Res 9(10): 1533-1539, 1994.
60. Essner R, Rhoades K, etal: IL-4 down regulates IL-1 and TNF gene expression in human monocytes. J Immunol 142:3857-3861, 1989.
61. Hart PH, Vitti GF etal: Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor a. interleukin 1 and prostaglandin E2. Pro Natl Acad Sci USA. 86-3803- 3807, 1989.
62. Miossec P, Briolay J etal: Inhibition of IL-6 production by IL-4. Calcif Tissue Int 46 (Suppl. 2):A 42 (abstract 163), 1990.
63. Takahashi N , Akatsu T, etal: osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600-2603, 1988.
64. Lacey DL , Erdmann JM etal: MC 3T3-EL osteoblastic cell express receptors for and responed to interleukin-4 J Bone Miner Res 6 (suppl. l):s225(abstract 686),1991.
65. Ueno K , Katayama T , etal: Interleukin 4 enhances in vitro mineralization in human ostesblast-like cells. Biochem Biophys Res Commun 189:1521-1526,1992.
66. Riancho JA , Zarrabeitia MT , etal: Effects of interleukin-4. on human osteoblast-like cells. Bone Miner 21 :53-61,1993.
67. Lawis DB, Liggit D etal: Mechanism of osteoporosis in IL-4 transgenic mice. J Bone Miner Res 7 (Suppl 1):S96 (abstract 15), 1992.
68. Gay CV: Osteoclast ultrastructure and enzyme histochemistry: Func-tional implications. In Rifkin BR. Gay CV(eds) Biology and physiology of the osteoclast. CRC press. Ann Arbor MI PP 129-150, 1992.
69. Anderson RE, Schraer H, Gay CV: Ultrastructural immunocy- tochemical localization of carbonic anhydrase in normal and calcitonin treated chick osteoclasts. Anat Rec 204:9-20, 1982.
70. Cao H, Gay CV : Effects of parathyroid hormone and calcitonin on carbonic anhydrase location in osteoclasts of culture embryonic chick bone. Experentia 41:1472-1474, 1985.
71. Zheng MG, Fan Y etal: Detection of carbonic anhydrase I in human osteoclast-like cells by in situ hybridization. J Bone Miner Res 8:113- 118, 1993.
72. Baron R, Neff L, etal: Evidence for a high and specific concentration of (Na~+,K~+ ) ATPase in the plasma membrane of osteoclast. Cell. 46:311,1986.
73. Reggio H, Bainton D, etal: Antibodies against lysosomal membranes reveal a 100,000-mol-wt protein that cross reacts with purified H~+ K~+ ATPase from gastric mucosa. J Cell Biol 99:1511, 1984.
74. Laitala T Vaananen K; Proton channel part of vacuolar H~+-ATPase and carbonic anhydrase I expression is stimulated in resorbing osteoclasts J Bone miner Res 8:119-126, 1993.
75. S Asotra, A.K Gupta etal: Carbonic anhydrase I mRNA expression in individual osteoclasts. Under "Resorbing" and "Non resorbing" conditions. J Bone Miner Res. 9(7): 1115-1122, 1994
76. MH Zheng, T-T. A lau etal: 173-estradiol suppresses gene expression of tartrate-resistant acid phosphatase and carbonic anhydrase I in o- variectomized rats. Calcif Tissue Int. 56:166-169, 1995.
77. Horton MA : Osteoclast-specific antigens. ISI Atlas Sci Immunol 1:35- 43, 1988.
78. Horton MA, Davies J: Perspectives: Adhesion receptors in bone. J Bone Miner Res 4,803-809, 1989.
79. Albeda SM, Buck CA : Integrins and other cell adhesion molecules. FASEB J. 4:2826-2880, 1990.
80. Ruoslahti E : Integrins. J Clin Invest 87:1-5, 1991.
81. Gehron-Robey P: Calcified tissue matrix: composition and regulation.Workshop C American Society of Bone and Research meeting. Atlanta pp1-15, 1990.
82. Grzesik WJ, Robey PG : Bone matrix RGD-glycoproteins: immunolo-calization and interaction with primary cell in vitro. J Bone Miner Res. 9,487-496, 1994.
83. Kukreja SC, D' Anza JJ, etal: Effect of kistrin on serum calcium in normal and hypercalcemic mice. J Bone Miner Res 7(S129):148,1992.
84. Kathleen L. King, James. J. D' Anza etalj Effects of kistrin on bone resorption in vitro and serum calcium in vitro. J Bone Miner Res 9(3) : 381-387, 1994.
85. Maciewicz RA , Etherington DJ: A comparison of four cathepsins (B. L. N and S) with collagenolytic activity from rabbit spleen. Biochem J. 256:433-440,1988.
86.Rifkin BR, Vernillo AT, Kleckner AP et ah Cathepsin B and L activities in isolated osteoclasts. Biochem Biophys Res Commun 179:63-69, 1991.
87. Bailey AJ, Etherington DJ In:Florkin M. Stolz E(eds) Comprehensive Biochemistry. Elsevier/North Holland Biomedical Press, Amsterdam pp299-460, 1980
88. Burleigh MC, Barrett AJ, Lazarus GS: Cathepsin B: a lysosomal enzyme that degrades native collagen Biochem J. 137:387-398, 1974.
89. Karhukorpi EK, Vihko P, Vaananen K : A difference in the enzyme contents of resorption lacunae and secondary lysosomes of osteoclasts. Acta Histochem. 92:1-11, 1992.
90. Van Noorden CJF, Everts V: Selective inhibition of cysteine proteinas- es by Z-Phe-AlaCHZF suppresses digestion of collagen by fibroblasts and osteoclasts. Biochem Biophys Res Commun 178:178-184, 1991.
91. Wooley DE: Mammalian collagenase In :Piez KA, Reddi AH (eds) Extracellular Matrix Biochemistry. Elsevier New York pp. 119-157. 1984.
92. Sakamoto S, Sakamoto M: Immunocytochemical localization of collagenase in isolated mouse bone cells. Biomed Res 5:29-38, 1984.
93. Delaisse JM, Eeckhout Y, Vaes G: Bone-resorbing agents affect the production and distribution of procollagenase as well as the activity of??collagenase in bone tissue. Endocrinology 123:264-276, 1988.
94. Partridge NC, Jeffrey JJ, Ehlich LS, etal: Hormonal regulation of the production of collagenase and of a collagenase inhibitor activity by rat osteogenic sarcoma cells. Endocrinology 120:1956-1962, 1987.
95. Jilka RL: Procollagenase associated with the noncalcified matrix of bone and its regulation by parathyroid hormone. Bone 10:353-358, 1989.
96. Delaisse JM , Eeckhout Y, Sear C, etal: A new synthetic inhibitor fo mammalian tissue collagenase inhibits bone resorption in culture. Biochem Biophy Res Commun 133:483-490,1985.
97. Chambers TJ, Fuller K : Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact J Cell Sci 76: 155- 165, 1985.
98. Chambers TJ, Darby JA, Fuller K : Mammalian collagenase predisposes bone surfaces to osteoclastic resorption. Cell Tissue Res. 241 : 671- 675, 1985.
99. Soriano P, Montgomery C etal: Targeted disruption of the c-src proto- oncogene lead to osteopetrosis in mice. Cell 64:693-697, 1991.
100.Kato I, Yoneda T etal: Osteoclasts deficiency in c-src tyrosine kinase fail to resorb bone in vitro and in vivo. J Bone Miner Res 6:(suppl): abstr 452, 1991.